Trial Profile

A Phase 2, Double-blind, Randomized, Placebo-controlled Study of Nelotanserin Versus Placebo in Subjects With Dementia with Lewy Bodies (DLB) or Parkinson's Disease Dementia (PDD) Who Have REM Sleep Behavior Disorder (RBD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 13 Aug 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nelotanserin (Primary)
Indications REM-sleep-behavior-disorder
Focus Registrational; Therapeutic Use
Sponsors Axovant Gene Therapies; Axovant Sciences; Sio Gene Therapies [CEASED]

22 Jun 2021 Results presented at the 7th Congress of the European Academy of Neurology
10 Dec 2018 Top-line results (n=34) are presented in an Axovant media release.
10 Dec 2018 Primary endpoint has not been met. (frequency of REM sleep), according to an Axovant media release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com